Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) started the day on Wednesday, with a price increase of 1.35% at $8.24, before settling in for the price of $8.13 at the close. Taking a more long-term approach, AUPH posted a 52-week range of $4.71-$10.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 3168.98%. Meanwhile, its Annual Earning per share during the time was 6.35%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 105.86%. This publicly-traded company’s shares outstanding now amounts to $143.83 million, simultaneously with a float of $128.71 million. The organization now has a market capitalization sitting at $1.18 billion. At the time of writing, stock’s 50-day Moving Average stood at $7.35, while the 200-day Moving Average is $6.08.
Aurinia Pharmaceuticals Inc (AUPH) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Aurinia Pharmaceuticals Inc’s current insider ownership accounts for 10.11%, in contrast to 38.65% institutional ownership. According to the most recent insider trade that took place on Nov 11 ’24, this organization’s Director sold 4,557 shares at the rate of 8.43, making the entire transaction reach 38,416 in total value, affecting insider ownership by 13,356. Preceding that transaction, on Nov 11 ’24, Company’s Director sold 5,241 for 8.43, making the whole transaction’s value amount to 44,182. This particular insider is now the holder of 12,672 in total.
Aurinia Pharmaceuticals Inc (AUPH) Earnings and Revenue Records
Aurinia Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 105.86% and is forecasted to reach 0.59 in the upcoming year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
Let’s observe the current performance indicators for Aurinia Pharmaceuticals Inc (AUPH). It’s Quick Ratio in the last reported quarter now stands at 5.11. The Stock has managed to achieve an average true range (ATR) of 0.32. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.35. Similarly, its price to free cash flow for trailing twelve months is now 41.02.
In the same vein, AUPH’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.16, a figure that is expected to reach 0.03 in the next quarter, and analysts are predicting that it will be 0.59 at the market close of one year from today.
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
If we take a close look at the recent performances of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), its last 5-days Average volume was 1.32 million that shows plunge from its year to date volume of 1.6 million. During the previous 9 days, stock’s Stochastic %D was recorded 42.74% While, its Average True Range was 0.33.
Raw Stochastic average of Aurinia Pharmaceuticals Inc (AUPH) in the period of the previous 100 days is set at 85.90%, which indicates a major rise in contrast to 70.76% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 47.73% that was higher than 44.27% volatility it exhibited in the past 100-days period.
